Affected by overseas public sentiment and newly issued regulatory requirements, Cabio Biotech (Wuhan) Co., Ltd. has made adaptive and phased adjustments to its production and operation plans. Up to now, the product production and sales have not yet fully resumed, and business operations have been severely disrupted, with normal operation unlikely to resume within three months.
In accordance with relevant regulations, the company's shares will be suspended from trading starting from July 27, 2026, and will resume trading on July 28, 2026. A risk warning will be implemented from the trading resumption date. During the risk warning period, the company's shares will not be traded on the Risk Warning Board of the Shanghai Stock Exchange and are not subject to the trading provisions of such board. The share price fluctuation limit will stay unchanged at 20%. The A-share abbreviation will be revised from "Cabio" to "ST Cabio", the A-share extended abbreviation will be adjusted from "Cabio Biotech" to "ST Cabio Biotech", while the stock code shall remain "688089".
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
In accordance with relevant regulations, the company's shares will be suspended from trading starting from July 27, 2026, and will resume trading on July 28, 2026. A risk warning will be implemented from the trading resumption date. During the risk warning period, the company's shares will not be traded on the Risk Warning Board of the Shanghai Stock Exchange and are not subject to the trading provisions of such board. The share price fluctuation limit will stay unchanged at 20%. The A-share abbreviation will be revised from "Cabio" to "ST Cabio", the A-share extended abbreviation will be adjusted from "Cabio Biotech" to "ST Cabio Biotech", while the stock code shall remain "688089".
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment